Carcinoma, Pancreatic Ductal
"Carcinoma, Pancreatic Ductal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Descriptor ID |
D021441
|
| MeSH Number(s) |
C04.557.470.200.025.232.750 C04.557.470.615.132.750 C04.588.274.761.750 C04.588.322.475.750 C06.301.761.750 C06.689.667.625 C19.344.421.750
|
| Concept/Terms |
Carcinoma, Pancreatic Ductal- Carcinoma, Pancreatic Ductal
- Carcinomas, Pancreatic Ductal
- Ductal Carcinoma, Pancreatic
- Ductal Carcinomas, Pancreatic
- Pancreatic Ductal Carcinomas
- Duct-Cell Carcinoma of the Pancreas
- Duct Cell Carcinoma of the Pancreas
- Pancreatic Ductal Carcinoma
- Ductal Carcinoma of the Pancreas
- Pancreatic Duct Cell Carcinoma
- Carcinoma, Ductal, Pancreatic
- Duct-Cell Carcinoma, Pancreas
- Carcinoma, Pancreas Duct-Cell
- Carcinomas, Pancreas Duct-Cell
- Duct Cell Carcinoma, Pancreas
- Duct-Cell Carcinomas, Pancreas
- Pancreas Duct-Cell Carcinoma
- Pancreas Duct-Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Pancreatic Ductal".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Carcinoma [C04.557.470.200]
- Adenocarcinoma [C04.557.470.200.025]
- Carcinoma, Ductal [C04.557.470.200.025.232]
- Carcinoma, Pancreatic Ductal [C04.557.470.200.025.232.750]
- Neoplasms, Ductal, Lobular, and Medullary [C04.557.470.615]
- Carcinoma, Ductal [C04.557.470.615.132]
- Carcinoma, Pancreatic Ductal [C04.557.470.615.132.750]
- Neoplasms by Site [C04.588]
- Digestive System Neoplasms [C04.588.274]
- Pancreatic Neoplasms [C04.588.274.761]
- Carcinoma, Pancreatic Ductal [C04.588.274.761.750]
- Endocrine Gland Neoplasms [C04.588.322]
- Pancreatic Neoplasms [C04.588.322.475]
- Carcinoma, Pancreatic Ductal [C04.588.322.475.750]
- Digestive System Diseases [C06]
- Digestive System Neoplasms [C06.301]
- Pancreatic Neoplasms [C06.301.761]
- Carcinoma, Pancreatic Ductal [C06.301.761.750]
- Pancreatic Diseases [C06.689]
- Pancreatic Neoplasms [C06.689.667]
- Carcinoma, Pancreatic Ductal [C06.689.667.625]
- Endocrine System Diseases [C19]
- Endocrine Gland Neoplasms [C19.344]
- Pancreatic Neoplasms [C19.344.421]
- Carcinoma, Pancreatic Ductal [C19.344.421.750]
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Pancreatic Ductal".
This graph shows the total number of publications written about "Carcinoma, Pancreatic Ductal" by people in this website by year, and whether "Carcinoma, Pancreatic Ductal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 6 | 1 | 7 |
| 2004 | 7 | 2 | 9 |
| 2005 | 6 | 3 | 9 |
| 2006 | 7 | 5 | 12 |
| 2007 | 6 | 3 | 9 |
| 2008 | 18 | 4 | 22 |
| 2009 | 14 | 2 | 16 |
| 2010 | 15 | 2 | 17 |
| 2011 | 27 | 4 | 31 |
| 2012 | 28 | 3 | 31 |
| 2013 | 28 | 3 | 31 |
| 2014 | 42 | 2 | 44 |
| 2015 | 33 | 4 | 37 |
| 2016 | 45 | 6 | 51 |
| 2017 | 43 | 7 | 50 |
| 2018 | 36 | 2 | 38 |
| 2019 | 43 | 6 | 49 |
| 2020 | 45 | 4 | 49 |
| 2021 | 50 | 5 | 55 |
| 2022 | 52 | 0 | 52 |
| 2023 | 42 | 1 | 43 |
| 2024 | 47 | 7 | 54 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Pancreatic Ductal" by people in Profiles.
-
Metabolic reprogramming by mutant GNAS creates an actionable dependency in intraductal papillary mucinous neoplasms of the pancreas. Gut. 2024 Dec 10; 74(1):75-88.
-
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells. Gut. 2024 Nov 11; 73(12):1984-1998.
-
DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites. Clin Epigenetics. 2024 Nov 10; 16(1):156.
-
The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024 Dec 31; 25(1):2421584.
-
Pancreatic Cancer-Associated Fibroblasts: Where Do We Go from Here? Cancer Res. 2024 Nov 04; 84(21):3505-3508.
-
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024 Nov 01; 14(11):2135-2161.
-
Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Pancreatology. 2024 Dec; 24(8):1265-1279.
-
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2024 Oct 15; 30(20):4609-4617.
-
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Future Oncol. 2024; 20(37):2915-2925.
-
Surgery for Borderline Resectable Pancreatic Ductal Adenocarcinoma: Preoperative Planning, Technical Considerations, and Building a Program. Surg Clin North Am. 2024 Oct; 104(5):1031-1048.